Tag
Elevated maternal third-trimester TRAb levels in Graves’ disease are linked to neonatal thyroid dysfunction and impaired neurodevelopment at 24 months, independent of neonatal thyroid status, highlighting the need for prenatal monitor
A propensity-weighted analysis suggests that shorter antithyroid drug therapy (<12 months) in Graves' disease patients with low baseline TRAb is broadly comparable to the standard 12-18 months in preventing relapse, supporting indiv
This review synthesizes 20 years of data on pediatric hyperthyroidism, highlighting shifts toward prolonged antithyroid drug therapy, reduced definitive treatments, and rising relapse rates, underscoring the need for individualized long-ter
In a large single-center cohort, Graves’ disease patients with preoperative TSH ≥10.0 μIU/mL had greater blood loss, larger preoperative thyroid enlargement, and longer operations, suggesting that avoiding iatrogenic hypothyroidism during s
This clinical review synthesizes findings from the PRETHYR study on antithyroid drug use in pregnant women, highlighting treatment transitions, biochemical predictors, and the impact of specialist-led management in Denmark.
A randomized trial reveals that adding L-carnitine and selenium to methimazole therapy significantly accelerates TRAb negativity, increases remission rates, and reduces cumulative drug exposure in patients with Graves’ disease.
The GRASS trial, a double-blind multi-centre RCT, found that adding 200 µg of selenium daily to standard antithyroid drug therapy does not increase remission rates or improve quality of life in patients with newly diagnosed Graves’ hy
